Henry J Fuchs Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Henry J Fuchs is President, Worldwide R&D of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 185,074 shares of BMRN, which is worth approximately $12.2 Million. The most recent transaction as insider was on Sep 13, 2024, when has been sold 12,098 shares (Common Stock) at a price of $84.9 per share, resulting in proceeds of $1,027,120. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 185K

6.14% 3M change

5.04% 12M change

Total Value Held $12.2 Million

HENRY J FUCHS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 13 2024	SELL Payment of exercise price or tax liability	$1,027,120 $84.9 p/Share	12,098 Reduced 6.14%	185,074 Common Stock
Apr 30 2024	BUY Grant, award, or other acquisition	$20,595 $68.65 p/Share	300 Added 0.15%	197,172 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$2,808,386 $83.87 p/Share	33,485 Reduced 14.54%	196,872 Common Stock
Mar 15 2024	BUY Grant, award, or other acquisition	-	18,240 Added 7.34%	230,357 Common Stock
Mar 05 2024	SELL Open market or private sale	$3,010,346 $85.18 p/Share	35,341 Reduced 14.28%	212,117 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	53,204 Added 17.7%	247,458 Common Stock
Dec 01 2023	BUY Grant, award, or other acquisition	-	17,750 Added 8.37%	194,254 Common Stock
Aug 10 2023	SELL Open market or private sale	$1,085,160 $90.43 p/Share	12,000 Reduced 6.38%	176,187 Common Stock
Apr 28 2023	BUY Grant, award, or other acquisition	$21,200 $66.88 p/Share	317 Added 0.18%	176,504 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$3,362,760 $93.41 p/Share	36,000 Reduced 16.06%	188,187 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$421,064 $87.74 p/Share	4,799 Reduced 2.1%	224,187 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	16,840 Added 6.85%	228,986 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	68,052 Added 24.29%	212,146 Common Stock
Mar 16 2022	SELL Payment of exercise price or tax liability	$182,346 $80.72 p/Share	2,259 Reduced 1.55%	143,753 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$947,145 $78.27 p/Share	12,101 Reduced 7.65%	146,012 Common Stock
Mar 15 2022	BUY Grant, award, or other acquisition	-	38,790 Added 19.7%	158,113 Common Stock
Mar 08 2022	BUY Grant, award, or other acquisition	-	12,840 Added 9.72%	119,323 Common Stock
Mar 22 2021	SELL Payment of exercise price or tax liability	$192,688 $78.52 p/Share	2,454 Reduced 2.26%	106,142 Common Stock
Mar 16 2021	SELL Payment of exercise price or tax liability	$174,417 $77.21 p/Share	2,259 Reduced 2.04%	108,596 Common Stock
Mar 15 2021	SELL Payment of exercise price or tax liability	$584,789 $78.39 p/Share	7,460 Reduced 6.31%	110,855 Common Stock
Mar 15 2021	BUY Grant, award, or other acquisition	-	15,320 Added 11.46%	118,315 Common Stock

Also insider at

MRTX

Mirati Therapeutics, Inc. Healthcare

HJF

Henry J Fuchs

President, Worldwide R&D

San Rafael, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMRN shares.

Notify only if

Value

Insider Trading

Get notified when an Biomarin Pharmaceutical Inc insider buys or sells BMRN shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOMARIN PHARMACEUTICAL INC

Track Activities on BMRN

Account